Please join us for an important discussion on the value of innovation and the role of government in promoting research commercialization in Oregon.
The purpose of this meeting is to:
– Discuss state of affairs and identify upcoming challenges and opportunities facing Oregon’s bioscience sector and correlating research institutions, including impact of: federal support for Oregon academic research institutions, impacts of Bayh-Dole Act, state investment in R&D and infrastructure, and private investment in startup companies and broader bioscience industry in Oregon.
Format: In a 2-hour meeting, beginning with 30 minutes of networking, selected speakers will present succinct, impactful examples of the benefits of investment in Oregon’s biosciences/tech sector and opportunities/challenges to growth. The event format will be a “roundtable discussion” where participants engage in a group conversation
Denise McCarty, Executive Director of Oregon Bioscience Association: “30,000 foot” overview of sector’s growth, potential landmines (federal and state) and opportunities for success.
Bernie Fox, CEO of UbiVac: Viewpoint of a private immuno-oncology company who has both partnered with pharmaceutical companies and opted to grow his company in Oregon.
Representative from Oregon University (TBA): Research and commercialization challenges, opportunities, and the impact of federal funding.